Role of natural killer t cells in the mouse colitis-associated colon cancer model

Scandinavian Journal of Immunology

Volumn 75, Issue 1, 2012, Pages 16-26

  Yoshioka, K ^a   Ueno, Y ^a   Tanaka, S ^a   Nagai, K ^a   Onitake, T ^a   Hanaoka, R ^a   Watanabe, H ^a   Chayama, K ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; AZOXYMETHANE; DEXTRAN SULFATE; INTERLEUKIN 13;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER MODEL; CELL POPULATION; COLITIS; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNE RESPONSE; KNOCKOUT MOUSE; LEUKOCYTE ACTIVATION; MALE; MONONUCLEAR CELL; MOUSE; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; COLITIS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NATURAL KILLER T-CELLS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 83455235501     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2011.02607.x     Document Type: Article

References (46)

1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
2. Feagins LA, Souza RF, Spechler SJ. Carcinogenesis in IBD: potential targets for the prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 2009;6:297-305.
3. Clevers H. At the crossroads of inflammation and cancer. Cell 2004;17:118:671-4.
4. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72:1605-21.
5. Baniyash M. Chronic inflammation, immunosuppression and cancer: new insights and outlook. Semin Cancer Biol 2006;16:80-8.
6. Matsuda JL, Mallevaey T, Scott-Browne J, Gapin L. CD1d-restricted iNKT cells, the 'Swiss-Army knife' of the immune system. Curr Opin Immunol 2008;20:358-68.
7. Bendelac A, Lantz O, Quimby ME, Yewdell JW, Bennink JR, Brutkiewicz RR. CD1 recognition by mouse NK1+T lymphocytes. Science 1995;268:863-5.
8. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immnol 2005;23:877-900.
9. Bendelac A, Savage PB, Teyton L. The biology of NKT cells. Annu Rev Immunol 2007;25:297-36.
10. van Dieren JM, van der Woude CJ, Kuipers EJ et al. Roles of CD1d-restricted NKT cells in the intestine. Inflamm Bowel Dis 2007;13:1146-52.
11. Wingender G, Kronenberg M. Role of NKT cells in the digestive system. IV. The role of canonical natural killer T cells in mucosal immunity and inflammation. Am J Physiol Gastrointest Liver Physiol 2008;294:G1-8.
12. Matsuda JL, Naidenko OV, Gapin L et al. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J Exp Med 2000;192:741-54.
13. Fuss IJ, Heller F, Boirivant M et al. Nonclassical CD1d-restricted NKT cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest 2004;113:1490-7.
14. Ishimitsu R, Yajima T, Nishimura H, Kawauchi H, Yoshikai Y. NKT cells are dispensable in the induction of oral tolerance but are indispensable in the abrogation of oral tolerance by prostaglandin E. Eur J Immunol 2003;33:183-93.
15. Brigl M, Bry L, Kent SC, Gumperz JE, Brenner MB. Mechanism of CD1d-restricted natural killer T cell activation during microbial infection. Nat Immunol 2003;12:1230-7.
16. Emoto M, Yoshizawa I, Emoto Y, Miamoto M, Hurwitz R, Kaufmann SH. Rapid development of a gamma interferon-secreting glycolipid/CD1d-specific Valpha14+ NK1.1- T-cell subset after bacterial infection. Infect Immun 2006;74:5903-13.
17. Saubermann LJ, Beck P, De Jong YP et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology 2000;119:119-28.
18. Ueno Y, Tanaka S, Sumii M et al. Single dose of OCH improves mucosal T helper type 1/T helper type 2 cytokine balance and prevents experimental colitis in the presence of Vα14 natural killer T cells in mice. Inflamm Bowel Dis 2005;11:35-41.
19. Ueno Y, Tanaka S, Miyake S, Yamamura T, Chayama K. Role of invariant natural killer T cells in the regulation of the inflammatory response in experimental colitis in mice. In: Croxford JL, Yamamura T, eds. The immuno-regulatory role of natural killer T cells in inflammatory disease. Kerala: Research Signpost, 2005:35-50.
20. Heller F, Fuss IJ, Nieuwenhuis EE, Blumberg RS, Strober W. Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 2002;17:629-38.
21. Kawano T, Cui J, Koezuka Y et al. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14NKT cells. Proc Natl Acad Sci USA 1998;95:5690-3.
22. Greten FR, Eckmann L, Greten TF et al. IKKβ links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004;118:285-93.
23. Tanaka T, Kohno H, Suzuki R, Yamada Y, Sugie S, Mori H. A novel inflammation-related mouse colon carcinogenesis model induced by azoxymethane and dextran sodium sulfate. Cancer Sci 2003;94:965-73.
24. Magnuson BA, Carr I, Bird RP. Ability of aberrant crypt foci characteristics to predict colonic tumor incidence in rats fed cholic acid. Cancer Res 1993;53:4499-504.
25. Lu H, Kyo E, Uesaka T, Katoh O, Watanabe H. A water-soluble extract from cultured medium of Ganoderma lucidum (Rei-shi) mycelia suppresses azoxymethane-induction of colon cancers in male F344 rats. Oncol Rep 2003;10:375-9.
26. Okamoto S, Watanabe M, Yamazaki M et al. A synthetic mimetic of CD4 is able to suppress disease in a rodent model of immune colitis. Eur J Immunol 1999;29:355-66.
27. Numata Y, Tazuma S, Ueno Y, Nishioka T, Hyogo H, Chayama K. Therapeutic effect of repeated natural killer T cell stimulation in mouse cholangitis complicated by colitis. Dig Dis Sci 2005;50:1844-51.
28. Ochoa-Repáraz J, Rynda A, Ascón MA et al. IL-13 production by regulatory T cells protects against experimental autoimmune encephalomyelitis independently of autoantigen. J Immunol 2008;81:954-68.
29. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008;101:277-348.
30. Miyamoto K, Miyake S, Yamamura T. A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells. Nature 2001;413:531-4.
31. Okayasu I, Ohkusa T, Kajiura K, Kanno J, Sakamoto S. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut 1996;39:87-92.
32. Eberl G, Lees R, Smiley ST, Taniguchi M, Grusby MJ, MacDonald HR. Tissue-specific segregation of CD1d-dependent and CD1d-independent NK T cells. J Immunol 1999;162:6410-9.
33. Kremer M, Thomas E, Milton RJ et al. Kupffer cell and interleukin-12-dependent loss of natural killer T cells in hepatosteatosis. Hepatology 2010;51:130-41.
34. Godfrey DI, MacDonald HR, Kronenberg M, Smyth MJ, Van Kaer L. NKT cells: what's in a name? Nat Rev Immunol 2004;4:231-7.
35. Berzofsky JA, Terabe M. A novel immunoregulatory axis of NKT cell subsets regulating tumor immunity. Cancer Immunol Immunother 2008;57:1679-83.
36. Berzofsky JA, Terabe M. NKT cells in tumor immunity; opposing subsets define a new immunoregulatory axis. J Immunol 2008;180:3627-35.
37. Seino K, Taniguchi M. Functionally distinct NKT cell subsets and subtypes. J Exp Med 2005;202:1623-6.
38. Heller F, Florian P, Bojarski C et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64.
39. Mandal D, Levine AD. Elevated IL-13Ralpha2 in intestinal epithelial cells from ulcerative colitis or colorectal cancer initiates MAPK pathway. Inflamm Bowel Dis 2010;16:753-64.
40. Terabe M, Swann J, Ambrosino E et al. A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance. J Exp Med 2005;202:1627-33.
41. Ambrosino E, Terabe M, Halder RC et al. Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis. J Immunol 2007;179:5126-36.
42. Shimamura M, Huang YY. Presence of a novel subset of NKT cells bearing an invariant V(alpha)19.1-J(alpha)26 TCR alpha chain. FEBS Lett 2002;516:97-100.
43. Treiner E, Duban L, Bahram S et al. Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1. Nature 2003;422:164-9.
44. Croxford JL, Miyake S, Huang YY, Shimamura M, Yamamura T. Invariant V(alpha)19i T cells regulate autoimmune inflammation. Nat Immunol 2006;7:987-94.
45. Kawachi I, Maldonado J, Strader C, Gilfillan S. MR1-restricted V alpha 19i mucosal-associated invariant T cells are innate T cells in the gut lamina propria that provide a rapid and diverse cytokine response. J Immunol 2006;176:1618-27.
46. Bannai M, Kawamura T, Naito T et al. Abundance of unconventional CD8(+) natural killer T cells in the large intestine. Eur J Immunol 2001;31:3361-9.